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Abstract
Abnormal activation of the Sonic hedgehog (SHH) pathway has been described in a wide variety of human cancers and in
cancer stem cells (CSCs), however, the role of SHH pathway in gastric CSCs has not been reported. In this study, we
investigated the possibility that abnormal activation of the SHH pathway maintained the characteristics of gastric CSCs.
First, we identified cancer stem-like cells (CSLCs) from human gastric cancer cell lines (HGC-27, MGC-803 and MKN-45) using
tumorsphere culture. Compared with adherent cells, the floating tumorsphere cells had more self-renewing capacity and
chemoresistance. The cells expressing CSCs markers (CD44, CD24 and CD133) were also significantly more in tumorsphere
cells than in adherent cells. More importantly, in vivo xenograft studies showed that tumors could be generated with 2610
4
tumorsphere cells, which was 100-fold less than those required for tumors seeding by adherent cells. Next, RT-PCR and
Western blot showed that the expression levels of Ptch and Gli1 (SHH pathway target genes) were significantly higher in
tumorsphere cells than in adherent cells. The results of quantitative real-time PCR were similar to those of RT-PCR and
Western blot. Further analysis revealed that SHH pathway blocked by cyclopamine or 5E1 caused a higher reduction in self-
renewing capacity of HGC-27 tumorsphere cells than that of adherent cells. We also found that SHH pathway blocking
strongly enhanced the efficacy of chemotherapeutic drugs in HGC-27 tumorsphere cells in vitro and in vivo but had no
significant effect in adherent cells. Finally, we isolated the tumorspheres from gastric cancer specimen, these cells also had
chemoresistance and tumorigenic capacity, and SHH pathway maintained the gastric CSLCs characteristics of tumorsphere
cells from primary tumor samples. In conclusion, our data suggested that SHH pathway was essential for maintenance of
CSLCs in human gastric cancer.
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Introduction
CSCs play an important role in cancer development, this
subpopulation within tumor possesses the characteristics of self-
renewing capacity, chemoresistance and tumorigenic capacity thus
may play a crucial role in the initiation, progression and
recurrence of cancer. Examining and manipulating the biochem-
ical pathways involved in those characteristics is one of the best
ways of contributing to CSCs, leading to the development of novel
drugs and treatment procedures. SHH pathway plays a critical
role in many CSCs, such as glioblastoma stem cells [1,2], CD34+
leukemic cells[3,4] and breast CSCs[5], in addition, it is crucial to
the development and homeostasis of gastric gland[6], abnormal
activation of the SHH pathway could result in gastric cancer[7,8],
however, the role of SHH pathway in gastric CSCs is not clear.
SHH pathway in mammalian cells is mediated by ligands
Shh[9]. In the absence of Shh, the transmembrane receptor
patched (Ptch) inhibits the activity of another transmembrane
protein, smoothened (Smo), resulting in inactivation of SHH
pathway [9,10]. Binding of Shh to Ptch abrogates the inhibitory
effect of Ptch, and Smo is derepressed, thereby activating
transcription factor Gli(Gli1,Gli2 and Gli3)[9,10]. Gli1 is a strong
positive activator of downstream target genes and is itself a
transcriptional target of SHH pathway [11]. Therefore, Gli1 is
considered a marker of SHH pathway abnormal activation
[10,12].
Recently, several types of CSCs or CSLCs have been identified
and isolated from malignant tumors [13–25]. In gastric cancer,
methodologically, it is difficult to isolate and amplify CSCs from
cell lines or tumor tissue specimens. At the present time, CD44
appears to be the most useful marker for prospective purification
of gastric CSCs, however, it is not highly specific for gastric CSCs
[26].
In this study, we isolated CSLCs from human gastric cancer cell
lines (HGC-27, MGC-803 and MKN-45) using tumorsphere
culturing in serum-free medium and identified the self-renewal
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tumorsphere cells; next, we examined the expression of SHH
pathway-related molecules, including Shh, Ptch, Smo, Gli1 and
Gli2 in tumorsphere cells and adherent cells, especially the
expression of Ptch and Gli1.Then, we blocked SHH pathway by
cyclopamine or control tomatidine, 5E1 or control PBS to
investigate whether the characteristics of CSLCs in tumorsphere
cells were maintained by abnormal activation of the SHH
pathway. Finally, we utilized primary gastric cancer samples to
analyze the functional aspects of SHH pathway in gastric CSLCs.
Cyclopamine is a cell-permeable steroidal alkaloid. It disrupts
cholesterol bio-synthesis and specifically antagonizes SHH signaling
pathwaythroughdirectinteractionwithSmo(smoothened),adistant
relative of G-protein-coupled receptors. It is a valuable tool for
studying the involvement of SHH signaling in the development of
various tumors. Tomatidine is a steroidal alkaloid that structurally
resembles cyclopamine, but lacks the capacity to inhibit SHH
signaling. It can be used as a negative control. 5E1 is an anti-Hh
monoclonal antibody, which neutralizes the SHH and IHH activity.
Results
1. Tumorsphere cells possessed the characteristics of
CSLCs
We grew HGC-27, MGC-803 and MKN-45 adherent cells in
serum-free medium described in the methods section. After 7 days,
tumorspheres consisting of approximately 50 to 100 cells were
observed (Fig. 1A).
The self-renewing capacity of these tumorspheres was assessed
by dissociating them into single cell and growing at a clonal density
of 1,000 cells per milliliter. After 2 weeks, single cell derived from
HGC-27 tumorsphere cells generated sub-tumorspheres at
41.83%63.13% compared with 8.17%62.40% of adherent cells,
moreover, in MGC-803 and MKN-45, the sub-tumorspheres
formation rate of tumorsphere cells were also higher than that of
adherent cells. (Fig. 1B). These data suggested that the self-
renewing capacity of tumorsphere cells was significantly higher
than that of adherent cells. Tumorsphere cells also showed an
increased ability to form colonies under anchorage-independent
conditions in a standard soft agar assay after 14 days in HGC-27
and MKN-45 (Fig. 1C).
We also performed a limiting dilution assay for spheroids
formation using HGC-27 tumorsphere cells and adherent cells,
respectively. As shown in Table S1, approximately 27–35% of
tumorsphere cells could produce spheroids, while less than 5% of
adherent cells could generate spheroids after 3 weeks culture. There-
fore, in the HGC-27 tumorsphere cells, we could estimate that the
spheroids-forming cells population comprised a maximum of 35%.
Chemoresistance is another characteristic of CSCs, so we
investigated whether a difference in chemoresistance existed
between tumorsphere cells and adherent cells. The results showed
that, after 48 hours, tumorsphere cells demonstrated significantly
greater resistance to drugs compared with adherent cells under the
same conditions (Fig. 1D). We also assessed chemoresistance of
HGC-27 tumorsphere cells and adherent cells to different
concentrations of drugs, however, both tumorsphere cells and
adherent cells did not show significantly chemoresistance to drugs
in a dose-dependent fashion (Fig. S1).
Next, we examined the expression of CD44 in dissociated
tumorsphere cells and adherent cells using immunofluorescent
assay and western blot. The results showed that the cells expressing
CD44 were significantly more in tumorsphere cells than in
adherent cells (Fig. 2A). Moreover, the expression of other CSCs
markers(CD24 and CD133) in tumorsphere cells and adherent
cells was examined by western blot, compared with tumorsphere
cells, the expression of CD24 was significantly lower in adherent
cells, while the expression of CD133 was similar (Fig. 2B).
Further, we fractionated HGC-27 cell by FACS sorting for CD44,
we found that CD44(+) cell fraction could generate more spheroid
colonies compared with CD44(2) cell fraction, moreover, the size
of spheroid colonies from CD44(+) cells was larger than those from
CD44(2) cells(Fig. 2C).
2. Tumorsphere cells could generate tumors upon
xenotransplantation
For xenograft studies, equal number (2610
4,2 610
5,2 610
6,
2610
7) of freshly dissociated tumorsphere cells or control adherent
cells was injected s.c. into each mouse (6 mice per group). The
results showed that tumors were generated with 2610
4 tumor-
sphere cells, which was 100-fold less than those required for tumor
seeding by adherent cells (Table 1). Moreover, tumorsphere cells
generated subcutaneous tumors with larger volume and shorter
time compared with those generated from adherent cells
(Fig. 3A,B). Thus, subcutaneous injection of low number of
tumorsphere cells confirmed that the spheroid cells retained
stronger tumorigenic capacity in nude mice than adherent cells.
H&E examination of xenografts derived from HGC-27 tumor-
sphere cells showed that these tumors closely resembled the
original human tumor, mainly containing differentiated cells
(Fig. 3C). Importantly, tumorspheres could be re-derived from the
xenotransplanted tumors (Fig. 3D), and they could form tumor
again (Fig. 3E). These data therefore indicated that the tumor-
sphere cells represented CSLCs that had tumorigenic capacity.
3. SHH pathway was higher expressed in tumorsphere
cells than in adherent cells
To investigate the link between SHH pathway and CSLCs
characteristics of tumorsphere cells, we first examined the mRNAs
expression of SHH pathway-related molecules, including Shh,
Ptch, Smo, Gli1 and Gli2 by RT-PCR. The results showed that all
of the mRNAs were high expressed in HGC-27 tumorsphere cells.
Compared with tumorsphere cells, the expression levels of Shh,
Ptch, Smo and Gli1 were significantly lower in adherent cells,
while the expression levels of Gli2 were similar to tumorsphere
cells. In MGC-803 and MKN-45, the expression levels of Shh,
Ptch and Gli1 were also significantly lower in adherent cells than
in tumorsphere cells, while the expression levels of Smo and Gli2
had no significant difference between adherent cells and tumor-
sphere cells (Fig. 4A).
In SHH pathway, Ptch and Gli1 are target genes, they are
considered as important markers of SHH pathway abnormal
activation. So, we further examined the expression levels of Ptch
and Gli1 by Western blot and quantitative real-time PCR.
When using Western blot, we found that the expression levels of
Ptch and Gli1 were also higher in tumorsphere cells than in
adherent cells (Fig. 4B). We next assessed the expression levels of
Ptch and Gli1 in xenografts from HGC-27 by quantitative real-
time PCR. Quantitative real-time PCR analyses of SHH target
genes (PTCH and GLI1) showed the same results of above semi-
quantitative RT–PCR (Fig. 4C).
4. SHH pathway blocking reduced the self-renewing
capacity and chemoresistance of HGC-27 tumorsphere
cells
To test for a possible role of SHH pathway in self-renewing
capacity of tumorsphere cells, we used cyclopamine or control
tomatidine, 5E1 or control PBS to block the pathway.
A Subcutaneous Xenograft Model
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17687Figure 1. The CSCs characteristics of tumorsphere cells. (A) Tumorspheres formed after 14 days. (B) The sub-tumorspheres formation ability of
tumorsphere cells (white bars) and adherent cells (black bars). *=P,0.05. Bars=1000mm. (C) The colonies formation ability of tumorsphere cells
(white bars) and adherent cells (black bars) under anchorage-independent conditions by soft agar assays. *=P,0.05. (D) Effect of 48 hours exposure
of tumorsphere cells (white bars) and adherent cells (black bars) to 1000 mM chemotherapeutic drug. Ox=oxaliplatin, Mi=mitomysin. *=P,0.05.
doi:10.1371/journal.pone.0017687.g001
A Subcutaneous Xenograft Model
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significantly reduction in capacity for the formation of sub-
tumorspheres in HGC-27 tumorsphere cells in a dose-dependent
fashion, but no such effect was observed in adherent cells (Fig. 5A).
We further evaluated whether treatment with cyclopamine would
affect the colonies formation capacity of HGC-27 tumorsphere
cells by anchorage -independent growth assay. Similarly, the
capacity to form colonies was reduced more in the tumorsphere
cells in a dose-dependent fashion relative to the adherent cells
(Fig. 5B).
Next, we investigated the effect of SHH pathway on
chemoresistance of HGC-27 tumorsphere cells, we treated the
dissociated cells with cyclopamine or control tomatidine for
48 hours, and then drug resistance of tumorsphere cells was
evaluated. When cyclopamine was followed by drugs, the
treatment resulted in a significantly enhanced overall cell death
rate. Best results were obtained when cyclopamine was combined
with Oxaliplatin plus Mitomycin (Fig. 5C). No such synergistic
effect was observed in adherent cells after exposure to drugs with
cyclopamine for 48 hours (Fig. 5D).
We also assayed the effect of different concentrations of
cyclopamine (2.5 uM, 5 uM, 10 uM) on cell death. Results
showed that cyclopamine alone to tumorsphere cells could make
a small but consistent decrease in the viable cell number.
Compared with HGC-27 tumorsphere cells, the effect of
cyclopamine on cell death to adherent cells was more significance
(Fig. 5C,D).
When SHH pathway was blocked by 5E1 or control PBS, the
results of self-renewing capacity and chemoresistance of tumor-
sphere cells and adherent cells were similar to those blocked by
cyclopamine or control tomatidine (Fig. S2).
5. SHH pathway blocking enhanced tumor response to
drugs in vivo
To test this hypothesis in vivo, we analyzed whether SHH
pathway blocking enhanced chemotherapy efficacy, cyclopamine
or control tomatidine was used to inhibit SHH pathway responses.
HGC-27 tumorsphere cells were allowed to grow into both rear
flanks of nude mice until the larger diameter of tumor reached
about 2 mm. Mice were then treated twice a week for 3 weeks with
cyclopamine or control tomatidine 24 hours before Oxaliplatin
delivery. In all treated mice, tumors treated with Oxaliplatin were
significantly smaller than those no treated with Oxaliplatin.
Moreover, tumors showed significantly greater tumor growth
inhibition when they were treated with Oxaliplatin in combination
with cyclopamine, the tumor response to chemotherapeutic drug
was enhanced by cyclopamine (Fig. 6A,B). We also investigated
whether SHH pathway blocked by 5E1 or control PBS enhanced
chemotherapy efficacy in vivo, the results showed that 10 mg/ml
5E1 treatment led to a significantly greater tumor growth
inhibition than those only treated with Oxaliplatin (Fig. 6A,B).
These data suggested that although standard chemotherapeutic
drugs delayed tumor outgrowth during the treatment, when they
were combined with cyclopamine or 5E1, the efficacy of
chemotherapy was significantly enhanced and also more sustained
after treatment interruption.
Next, to investigate whether blocking SHH pathway in vivo had
a specific effect on HGC-27 tumorsphere cells. Mice were only
treated cyclopamine at the right rear flank or control tomatidine at
the left rear flank (twice a week for 3 weeks) when tumors from
HGC-27 tumorsphere cells reached about 2 mm, after 3 weeks,
we performed a limiting dilution assay for spheroids formation
using tumor cells treated with cyclopamine and treated with
tomatidine, respectively. As shown in Table S2, approximately 9–
15% of cells from xenotransplanted tumor treated with tomatidine
could produce spheroids, while less than 2.5% of cells from
xenotransplanted tumor treated with cyclopamine could generate
spheroids. Therefore, blocking SHH pathway in vivo could reduce
the numbers of gastric CSLCs.
6. SHH pathway maintained the gastric CSLCs
characteristics of tumorsphere cells from primary tumor
samples
To determine whether SHH pathway could be involved in the
gastric CSCs characteristics of tumorsphere cells from gastric
cancer tissue, we utilized primary gastric cancer samples to
analyze the functional aspects of SHH pathway in gastric CSLCs.
First, we grew freshly dissociated bulk cells from gastric cancer
specimens in serum-free medium described in the methods section,
after 10 days, tumorspheres were observed(Fig. 7A,B). Then we
investigated chemoresistance and tumorigenic capacity of the
tumorsphere cells from gastric cancer tissue. The results showed
that tumorsphere cells from gastric cancer tissue demonstrated
significantly greater resistance to drugs than bulk cells under the
same conditions(Fig. 7C). Moreover, freshly dissociated bulk cells
from gastric cancer specimens injected at 2610
7 cells per mouse
were capable of establishing subcutaneous tumors, while as little as
2610
4 of the tumorsphere cells from gastric cancer specimens
could form tumors (Table 1), the xenografts tumors that resulted
from injection of tumorsphere cells presented the same histopa-
thology features as their respective human tumor (Fig. 7F). These
results showed that tumorsphere cells from gastric cancer tissue
possessed the characteristics of CSLCs. Next, we observed the
effect of SHH pathway blocking on chemoresistance of tumor-
sphere cells in vitro and tumor response to drugs in vivo. The
results showed that cyclopamine or 5E1 could resulted in a
significantly enhanced overall cell death rate (Fig. 7D) and the
tumor response to drug (Fig. 7E).
Figure 2. The expression of CSCs markers in tumorsphere cells and adherent cells. (A) Immunofluorescence (left panel) and western
blotting (right panel) analysis of CD44 (green color) on mechanically dissociated tumorsphere cells and adherent cells. Nuclei were counterstainedb y
DAPI (blue color). TCs=tumorsphere cells, ACs= adherent cells. Bars=100mm. (B) The expression of CD24 and CD133 in tumorsphere cells and
adherent cells by western blotting, b-actin was provided as a control. (C) The tumorspheres formation capacity of HGC-27 CD44(+) cells and CD44(2)
cells. *=P,0.05. Bars=1000mm.
doi:10.1371/journal.pone.0017687.g002
Table 1. Subcutaneous tumor growth in nude mice.
HGC-27 MGC-803 MKN-45
Gastric tumor
samples
Cell injected ACs TCs ACs TCs ACs TCs Bulk cells TCs
2610
4 0/6 2/6 0/6 1/6 0/6 2/6 0/6 2/6
2610
5 0/6 5/6 0/6 4/6 0/6 5/6 0/6 5/6
2610
6 3/6 6/6 2/6 5/6 2/6 5/6 0/6 6/6
2610
7 5/6 6/6 3/6 6/6 4/6 6/6 2/6 2/6
Tumorsphere cells (TCs) have stronger tumorigenic capacity than adherent
cells(ACs) and bulk cells.
doi:10.1371/journal.pone.0017687.t001
A Subcutaneous Xenograft Model
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CSCs share many characteristics with tissue stem cells, such as
self-renewal, proliferation, chemoresistance, and are primarily
responsible for sustaining the growth of tumors [27,28]. Many
investigators have used fluorescence-activated cell sorting to identify
and isolate CSCs and determined that these cells can form spheres
in specialized serum-free medium. In this study, we took the
opposite approach by developing tumorsphere cells and then
determining whether these cells acquired CSCs characteristics.
We used a defined serum-free medium consisting of EGF, FGF-
2, B-27 supplement and N-2 supplement to maintain gastric
cancer cell lines. These conditions had been used before to
maintain endogenous neural stem/progenitors and tumor stem
cells from human tumors and tumor cell lines. For example,
Kondo et al. [24] characterized the C6 rat tumor cell line in vitro
and in vivo and observed a small population of stem-like cells
derived from the well-characterized side population. Setoguchi
et al. [29] demonstrated cancer stem-like cell potential in other
cancer cell lines, including the MCF7 breast cancer line, B104
neuroblastoma, and HeLa adenocarcinoma.
At our experiment, we used three gastric cancer cell lines
(HGC-27, MKN-45 and MGC-803) to culture tumorspheres.
HGC-27 cell line was established by culture of the metastatic
lymph node from a gastric cancer patient diagnosed histological as
undifferentiated carcinoma. MKN-45 was established from the
poorly differentiated adenocarcinoma of the stomach of a 62-year-
old woman. MGC-803 is a epithelial poorly differentiated human
gastric muco-adenocarcinoma cell line from a 74-year-old man.
Two different approaches have typically been used to identify
CSCs in published studies [30,31]. One is an in vitro method
termed ‘‘spheroid colony formation,’’ and another is in vivo
method involving implantation of candidate CSCs under the skin
of immunodeficient mice.
The former method involves culturing candidate CSCs in
culture dishes specially coated for noncell attachment with serum-
free media containing epidermal growth factor and basic fibroblast
growth factor. The growth of spherical colonies after a few weeks is
considered indicative of self-renewal ability, and would be
consistent with a CSC phenotype. The latter method—growth
of cells in immunodeficient mice—is needed to demonstrate true
tumorigenicity and is generally regarded as the gold standard for
Figure 3. Subcutaneous tumor growth in nude mice. (A) Subcutaneous tumor growth in nude mice after injection of HGC-27 tumorsphere cells
(2610
5) into the left rear flank of each mouse and equal numbers of adherent cells into the right rear flank of each mouse. (B) Size of subcutaneous
tumor following injection of 2610
5 HGC-27 tumorsphere cells, 2610
5 HGC-27 adherent cells and 2610
6 HGC-27 adherent cells. (C) H&E staining
analysis of xenografts derived from HGC-27 tumorsphere cells. Bar=100 mm. (D) Tumorspheres derived from xenografts. Bar=1000 mm. (E)
Subcutaneous tumor growth in nude mice after injection of tumorsphere cells (2610
5) derived from xenografts.
doi:10.1371/journal.pone.0017687.g003
A Subcutaneous Xenograft Model
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that these two approaches generally provide similar results in
evaluating candidate CSCs for many solid tumors.
At present, gastric CSCs have not specific surface makers, so, we
developed tumorsphere cells and then determined whether these
cells acquired CSCs characteristics, including self-renewing
capacity, chemoresistance and tumorigenic capacity.
Our data showed that gastric cancer cell lines (HGC-27, MGC-
803, MKN-45) grown in a defined serum-free medium could form
tumorspheres that contained cells behaving like CSLCs. In vitro,
tumorsphere cells showed an increased ability to form colonies in
soft agar under anchorage-independent conditions and an
increased ability to form sub-tumorspheres. We also showed that
the self-renewal ability to form sub-tumorspheres of HGC-27
tumorsphere cells had a increase at passages 2 to 8 (from 44.5% up
to 70.5%), and then it maintained a relatively stable proportion
after 8 or more passages when grown at clonal density (Fig. S3).
These data suggested that the proliferative potential of tumor-
sphere cells was maintained after extended passages. In addition,
tumorsphere cells in vitro were more resistant to Oxaliplatin and
Figure 4. The expression of SHH pathway-related molecules. (A) The mRNA expression of Shh, Ptch, Smo, Gli1 and Gli2 in tumorsphere cells
and adherent cells was analyzed by RT-PCR. The expression of GAPDH was used as a control. (B) The protein expression of SHH pathway target genes
(Ptch and Gli1) was analyzed by Western blotting, b-actin was provided as a control. TCs=tumorsphere cells, ACs= adherent cells. (C) Quantitative
real-time RT–PCR analyses of SHH pathway target genes (Ptch and Gli1) showed the same results of the semi-quantitative RT–PCR. Results were
calculated as meant+s.d. values from triplicate measurements of three separate experiments. TCs=Tumorsphere cells, ACs=adherent cells.
doi:10.1371/journal.pone.0017687.g004
A Subcutaneous Xenograft Model
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that tumorsphere cells consist of enriched numbers of CSLCs,
which potentially made them less susceptible to the actions of both
Oxaliplatin and Mitomycin. In vivo, tumorsphere cells could
generate tumors upon xenotransplantation at a higher rate than
adherent cells. Moreover, tumorsphere cells generated subcuta-
neous tumors with larger volume and shorter time compared with
those generated from adherent cells, Importantly, tumorspheres
could be re-derived from the xenotransplanted tumors, and they
could form tumor again, these data suggested that tumorspheres
were enriched in CSLCs.
In our study, adherent cells presumably contained a relatively
low percentage of CSCs, as no method for isolation or removal of
these cells was used. It may be argued that it is this small
population of CSCs that is responsible for tumor formation.
Regardless, more CSCs were evident in the tumorsphere cells,
which may explain its more aggressive behavior.
Next, we investigated whether the characteristics of CSLCs in
tumorspheres were maintained by abnormal activation of the
SHH pathway. First, we demonstrated that mRNA expression
levels of SHH pathway-related molecules (Shh, Ptch and Gli1)
were significantly higher in tumorsphere cells than in adherent
Figure 5. Effect of SHH pathway blocking on self-renewing capacity and chemoresistance. (A) The sub-tumorspheres formation ability of
HGC-27 tumorsphere cells and adherent cells treated with different concentrations of cyclopamine or control tomatidine (open circle=cyclopa-
mine;closed circle=control tomatidine). Black lines are tumorsphere cells, red are adherent cells. *=P,0.05. TCs=tumorsphere cells. Bars=1000mm.
(B) The colonies formation of HGC-27 tumorsphere cells and adherent cells treated with different concentrations of cyclopamine or control
tomatidine under anchorage-independent conditions (open circle= cyclopamine;closed circle=control tomatidine). Black lines are tumorsphere
cells, red are adherent cells. *=P,0.05. TCs=tumorsphere cells. (C) Percentage of cell viability was analyzed on HGC-27 tumorsphere cells and
adherent cells (D) after exposure to different concentrations of cyclopamine or 5 uM cyclopamine with different drugs for 48 hours. Control group is
tomatidine. Cyc=cyclopamine, Ox=oxaliplatin, Mi=mitomysin. *=P,0.05.
doi:10.1371/journal.pone.0017687.g005
A Subcutaneous Xenograft Model
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examined the expression levels of SHH pathway target genes (Ptch
and Gli1) by Western blot and quantitative real-time PCR, the
results were similar to those of RT-PCR. Second, inhibition of
SHH pathway activity by cyclopamine or 5E1 led to decreased
self-renewal capacity and increased sensitivity to drugs in HGC-27
tumorsphere cells, but these effects were not pronounced in
adherent cells. In vivo, in all treated mice, tumors treated with
Oxaliplatin were significantly smaller than those no treated with
Oxaliplatin, after treatment with cyclopamine or 5E1, the tumor
response to chemotherapeutic drugs was enhanced. These data
suggested that although standard chemotherapeutic drugs delayed
tumor outgrowth during the treatment, when they were combined
with cyclopamine, the efficacy of chemotherapy was significantly
enhanced and also more sustained after treatment interruption.
Finally, we utilized primary gastric cancer samples to analyze
the functional aspects of SHH pathway in gastric CSLCs. Results
showed that tumorsphere cells from gastric cancer specimen also
had chemoresistance and tumorigenic capacity, moreover SHH
pathway blocking reduced the chemoresistance of tumorsphere
cells and enhanced tumor response to drugs in vivo.
As for chemoresistance, several features of CSCs may make
them hard to eliminate. CSCs are relatively quiescent and this
allows them to escape from chemotherapeutic regimens that
typically target actively cycling cells. Moreover, as shown for their
normal counterpart, CSCs have been proposed to exhibit high
level expression of multidrug transporter family genes, likely
resulting in more efficient efflux of chemotherapeutic drugs and
innate multidrug resistance, In addition, signaling pathways, such
as Wnt, Hedgehog or Notch, are dysregulated in CSCs leading to
tumor development. The development of an efficient therapeutic
approach would therefore require the identification of distinctive
molecular pathways active in CSCs and the identification of agents
that can either block CSC proliferation or induce CSC
differentiation, thus enhancing sensitivity to chemotherapeutic
drugs. So, important factors affecting the chemoresistance of CSCs
are intrinsic factors. The microenvironment, or niche, may
influence the ability of CSCs to proliferate, migrate or invade.
The niche is an anchoring site for CSCs, and adhesion molecules
or microenvironmental soluble molecules, including growth factors
and cytokines, can significantly contribute to the refractoriness to
therapy. Although inhibition of SHH pathway by cyclopamine or
5E1 would be a useful strategy, in our study, we demonstrated that
receptor component Ptch and transcription factor Gli1 were also
high expressed in tumorsphere cells. So, Ptch or Gli1 might be an
alternative target for treatment of gastric cancer. One possible
strategy is to use small interfering RNA (siRNA) or shRNA specific
for Ptch or Gli1, but gastric CSLCs in tumorsphere cells have not
been completely purified, we need to further purify the gastric
CSLCs, so this work will be done in our further study.
In conclusion, we showed that SHH pathway could be involved
in the self-renewal, proliferation, drug resistance and tumorigenic
of tumorsphere cells and suggest that strategies aimed at inhibiting
SHH pathways represent a rationale therapeutic approach to
target gastric CSCs.
Materials and Methods
Animal Ethics Statement
Male athymic nude mice(nu/nu), 6 to 8 weeks old, were
obtained from Beijing Vital-River Lab Animal Technology Co.
Ltd (SCXK JING 2007-0001) and were housed under pathogen-
free conditions in the barrier animal facility. All mice were
conducted under approved guidelines of Laboratory Animal
Figure 6. Effect of SHH pathway blocking on tumor response to drugs in vivo. (A) Subcutaneous tumors derived from 2610
5 HGC-27
tumorsphere cells grown in nude mice 4 weeks after i.p. treatment with PBS or oxaliplatin in combination with 10 mM control tomatidine at the left
rear flank around the tumor, or oxaliplatin in combination with 10mM cyclopamine at the right rear flank around the tumor, or oxaliplatin in
combination with 10 ug/ml 5E1 at the right rear flank. Tom=tomatidine, Cyc=cyclopamine, Ox=oxaliplatin. TCs=tumorsphere cells. (B) Tumor size
derived as in (A) after 20 days. Tom=tomatidine, Cyc=cyclopamine, Ox=oxaliplatin.
doi:10.1371/journal.pone.0017687.g006
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PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17687Figure 7. SHH pathway maintained the gastric CSLCs characteristics of tumorsphere cells from primary tumor samples. (A, B)
Tumorspheres from gastric cancer specimen formed after 2 weeks later. Bars=1000 mm. (C) Effect of 48 hours exposure of tumorsphere cells (white
bars) and bulk cells (black bars) to 1000 mM chemotherapeutic drug. Ox=oxaliplatin, Mi=mitomysin. *=P,0.05. (D) Cell viability was analyzed on
tumorsphere cells from gastric cancer specimen after exposure to cyclopamine or 5E1 with different drugs for 48 hours. Control group is PBS.
Cyc=cyclopamine, Ox=oxaliplatin, Mi=mitomysin. (E) Subcutaneous tumors derived from 2610
5 tumorsphere cells from gastric cancer
specimen after i.p. treatment with PBS or oxaliplatin in combination with 10mM control tomatidine at the left rear flank around the tumor, or
A Subcutaneous Xenograft Model
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2002-001).
Culture of adherent cells, tumorspheres and sub-
tumorspheres
Human gastric cancer cell lines (HGC-27,MGC-803 and
MKN-45) obtained from Peking Union Medical College was
cultured in 1640 medium containing 10% fetal bovine serum
(FBS) and plated at the density of 1610
6 live cells per 75-cm
2 flask.
When the cells attached, we passaged them upon confluence.
Tumorspheres were derived by placing the adherent cells into
serum-free 1640 culture medium containing 1% N-2 supplement
(Invitrogen), 2% B-27 supplement (Invitrogen), 1% antibiotic
mixture (Gibco), 20 ng/ml human FGF-2(Chemicon), and
100 ng/ml EGF (Chemicon), and the adherent cells were plated
in 24-well ultra-low attachment plate (Corning) at 500 cells per
well. 2 weeks later, plates were analyzed for tumorspheres
formation and were quantified using an inverted microscope
(Olympus) at 406and 1006magnification.
After primary tumorspheres reached the size of approximately
200–500 cells per sphere, the tumorspheres were dissociated at the
density of 1,000 cells per milliliter and 100 mL single cell
suspension was seeded in each well of 24-well ultra-low attachment
plate (Corning) in serum-free medium described above. Each well
was examined for single cell, and only the wells that contained
single cell were marked. 2 weeks later, wells were analyzed for sub-
tumorspheres formation. Normal adherent cells were used as
control for the capacity to form sub-tumorspheres. To test the link
between SHH pathway and the formation of sub-tumorspheres,
we treated the dissociated cells with cyclopamine (2.5 mM, 5 mM,
10 mM) or control tomatidine, 5E1(10 ug/ml) or control PBS and
observed the formation of sub-tumorspheres.
Gastric cancer tissue specimen
The human fresh, sterile gastric cancer tissue specimens were
obtained in accordance with the ethical standards of the
institutional committee on human experimentation from 15
patients (age range 70–85 years) undergoing a gastric cancer
resection, after obtaining informed consent from the patients
(Table S3).
Then the specimens were immersed in 95% ethanol for 2–3 sec
to avoid contamination, and washed with phosphate-buffered
saline (PBS) and antibiotics several times to remove the blood.
After these, the surface of the cancer tissue specimens was removed
and the inner parts were cut into 1–3 mm
3-sized pieces. Then they
were digested in collagenase and dispase solution at 37uC, after
4 h incubation, the solution containing the digested tissues was
centrifuged to remove the collagenase solution. The cell pellet was
washed once with 1640 medium before being suspended into
serum-free 1640 medium containing 1% N-2 supplement, 2% B-
27 supplement, 1% antibiotic mixture, 20 ng/ml human FGF-2,
100 ng/ml EGF and plated in 24-well ultra-low attachment plate.
All cultures were incubated at 37uC in incubators supplied with
humidified air and 5% CO2.
Anchorage-independent growth assay
For observing the self-renewing capacity further, soft agar assay
was used to determine the colonies formation of tumorsphere cells
and adherent cells under anchorage-independent conditions. Each
well of a six-well plate was coated with 1 mL of 10% FBS 1640
medium with 1% agarose. After 20 min of incubation at 37uC,
equal numbers (500) of tumorsphere cells or adherent cells were
added in 1 mL of 10% FBS 1640 medium with 0.5% agarose. To
test the link between SHH pathway and the colonies formation
under anchorage-independent conditions, we treated the dissoci-
ated cells with cyclopamine (2.5 mM, 5mM, 10mM) or control
tomatidine, 5E1(10 ug/ml) or control PBS. Cells were incubated
for 14 days under standard conditions (37(C, 5% CO2) and with
the addition of 300mL of medium every 3 days to hydrate the
exposed agarose. At the end of the incubation period, wells were
examined under a light microscope and the number of colonies
larger than 50mm was counted per well.
Immunofluorescent analysis
For immunofluorescent staining, mechanically dissociated
tumorsphere cells or adherent cells were fixed in 4% paraformal-
dehyde (Sigma) for 15–20 min at room temperature. Cells were
washed three times with PBS and incubated for 10 min in blocking
buffer which contained 10% goat serum, then incubated with
FITC-conjugated anti-human CD44 (Biolegend) diluted at 1:50
overnight at 4(C. Nuclei were visualized by DAPI (Sigma). PBS
was used to replace the primary antibody and served as a negative
control.
Chemoresistance assay
Rates of resistance to drugs were assessed using MTT assay.
Briefly, 2000 healthy tumorsphere cells or adherent cells per well
were plated in 96-well plates in 200mL 1640 medium (4 wells per
group) with 1000mM chemotherapeutic drugs (Oxaliplatin,
Mitomycin or Oxaliplatin plus Mitomycin) or control PBS. At
each time point (0, 24, 48 h), 20mL MTT solution was added to
each well and the plate was incubated for 4 hours at 37uC, then
the medium was replaced by 150 mL DMSO. To assess the effect
of SHH pathway on drug resistance of tumorsphere cells or
adherent cells, we treated the dissociated cells with cyclopamine
(5 mM) or control tomatidine, 5E1 (10 ug/ml) or control PBS for
48 hours. MTT assay is based on mitochondrial conversion of
MTT to yellowish formazan, being indicative of the number of
viable cells. The number of viable cells was evaluated by
absorbance OD450 nm (Abs) using Model 680 microplate reader.
Western blot analysis
For Western blot analyses, protein was harvested from cells
plated to 70% to 80% confluence. Tumorsphere cells or adherent
cells were lysed directly in nuclear lysis buffer to collect whole cell
extracts. Protein samples for Western blot were prepared by
boiling after the addition of denaturing sample buffer. Then,
proteins were separated using SDS-PAGE on an 8% or 15% gel,
transferred onto nitrocellulose membrane by PowerPac (BIO-
RAD). Membranes were incubated at 4uC overnight with primary
antibody, and subsequently incubated with horseradish peroxidase
–conjugated secondary antibodies for 1 h at room temperature.
Finally, protein bands were visualized using chemiluminesce
(Santa Cruz) exposure on BioMax film (Kodak). The following
concentrations were used for primary antibodies: anti-CD44 1:100
(Santa Cruz), anti-CD24 1:100 (Santa Cruz), anti-133 1:100(Santa
Cruz), anti-Ptch 1:300 (Santa Cruz), anti-Gli1 1:300 (Santa Cruz),
anti-actin: 1:1000 (Santa Cruz).
oxaliplatin in combination with 10mM cyclopamine at the right rear flank around the tumor. Tom=tomatidine, Cyc=cyclopamine, Ox=oxaliplatin.
TCs=tumorsphere cells. (F) H&E staining analysis of human tumor and xenografts derived from tumorsphere cells. Bar=100 mm.
doi:10.1371/journal.pone.0017687.g007
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Total RNA was extracted by the guanidine isothiocyanate–
phenol extraction method using the Trizol reagent (Invitrogen) as
specified by the manufacturer. Two micrograms of total RNA
were reverse transcribed using AMV reverse transcriptase
(TaKaRaBio) to produce cDNAs. Amplification was performed
in a GeneAmp 2700 thermal cycler (Applied Biosystems). The
semi-quantitative reverse transcription (RT)–PCR and quantita-
tive real-time PCR were carried out using primer sequences listed
in Table 2. For semi-quantitative RT–PCR, we showed data
within linear range by performing 25–35 cycles of PCR. For
quantitative real-time PCR, the expression level of each mRNA
was normalized with that of GAPDH mRNA.
S.c. xenograft model
For xenograft studies, equal number (2610
4,2 610
5,2 610
6,
2610
7) of freshly dissociated cells was suspended in 200 mL PBS,
the tumorsphere cells were injected s.c. into the left rear flank of
each mouse (6 mice per group) and the adherent cells were
injected s.c. into the right rear flank of each mouse, we examined
the tumorigenic capacity of tumorsphere cells and adherent cells.
Next, tumorsphere cells were allowed to grow into the both rear
flanks of nude mice until the larger diameter of tumor reached
about 2 mm, mice were then i.p. treated with PBS or oxaliplatin
(0.25 mg/kg, once a week for 4 weeks) in combination with
cyclopamine (10 mM, twice a week for 3 weeks) at the right rear
flank and control tomatidine (10 mM, twice a week for 3 weeks) at
the left rear flank, or in combination 5E1(10 ug/ml, twice a week
for 3 weeks) at the right rear flank and in combination with control
PBS(10 ug/ml, twice a week for 3 weeks) at the left rear flank,
cyclopamine and tomatidine, or 5E1 and PBS were injected s.c.
around the tumor. When tumors in the control group exceeded
1.5 cm in the larger diameter, mice were killed by CO
2
asphyxiation according to protocol, and the tumors were excised.
Tumors were weighed and measured, and a portion of each was
placed in 10% formalin for immunohistochemistry and H&E
staining. Tumor size was calculated every 2 days using the
formula: (p/6)6larger diameter6(smaller diameter)
2.
H&E
The excised tumors from male athymic nude mice were fixed in
10% formalin, embedded in paraffin, and processed by standard
histological methods. From each selected paraffin block, 5mm
serial sections were cut. Then tissue sections were stained for H&E
to assess morphology.
Statistical analysis
All experiments were repeated at least three times and
representative results are presented. Where applicable, quantita-
tive data were presented as means (SD. Tumorsphere formation
and tumor growth curves were analyzed by ANOVA with an
SPSS10.0 statistical software. Two groups were compared by the
Student’s t-test, P,0.05 was considered significant.
Supporting Information
Figure S1 The chemoresistance of HGC-27 tumor-
sphere cells and adherent cells to different concentra-
tions of drugs. Figure showed that HGC-27 tumorsphere cells
demonstrated significantly greater resistance to different concen-
trations (125mM, 250mM, 500mM and 1000mM) of drugs
(Oxaliplatin, Mitomycin) compared with the adherent cells after
48 hours, however, both tumorsphere cells and adherent cells did
not show significantly chemoresistance to drugs in a dose-
dependent fashion. White bars=1 day. Black bars=2 day.
(TIF)
Figure S2 Effect of anti-SHH antibody 5E1 on the self-
renewing capacity and chemoresistance. Figure showed
that 10mg/ml 5E1 treatment did not led to decrease in the
capacity for the formation of sub-tumorspheres in HGC-27
adherent cells but a significantly greater reduction (13.5%) in
HGC-27 tumorsphere cells. Similarly, the capacity to form
colonies in soft agar was reduced more in the HGC-27
tumorsphere cells (12.6%) relative to the adherent cells. The
effect of 5E1 on cell death to HGC-27 adherent cells was more
significance than tumorsphere cells, but no such synergistic effect
was observed in adherent cells after exposure to drugs with 5E1
for 48 hours. When 5E1 was followed by drugs in HGC-27
tumorsphere cells, the treatment resulted in a significantly
enhance overall cell death rate. Best results were obtained when
5E1 was combined with Oxaliplatin plus Mitomycin. Control
group is PBS. *=P,0.05. Bars=1000mm.
(TIF)
Figure S3 The self-renewal ability to form sub-tumor-
spheres of HGC-27 tumorsphere cells during serial
passages. Figure showed that the self-renewal ability to form
sub-tumorspheres of HGC-27 tumorsphere cells had a increase at
passages 2 to 8 (from 44.5% up to 70.5%), and then it maintained
a relatively stable proportion after 8 or more passages when grown
at clonal density. Data represent mean 6 SD of three independent
experiments.
(TIF)
Table S1 Limiting dilution assay for spheroid colony
formation. Tumorsphere cells and adherent cells were counted
by cytometer, original cell solutions with the concentration of
500 cells/ml were inoculated in 48-well ultra-low attachment
plates by 100 ul/well i.e. estimated cell number per well was 50
cells. Limiting dilution of cell solutions were carried out by the
ratio of 1/5, 1/10 and 1/50 for tumorsphere cells and adherent
cells, and the cells were inoculated in 48 wells respectively. After
3 weeks culture, spheroid colonies were counted in each group.
The results showed that approximately 27–35% of tumorsphere
cells could produce spheroid colonies, while less than 5% of
adherent cells could generate spheroid colonies after 3 weeks
culture. Therefore, within the tumorsphere cells, we could
Table 2. Primers and conditions used for RT-PCR and real-
time PCR.
Gene RT-PCR Real-time PCR
SHH 59-CGCACGGGGACAGCTCGGAAGT-39
59-CTGCGCGGCCCTCGTAGTGC -39
PTCH 59-GCCGTGCCCGTGGTCAT-39
59-CCCATTGAGAACGCCGAGGAT-39
59-TCTCCAATCTT-
CTGGCGAGT-39
59-TGGGATTAAA-
AGCAGCGAAC-39
SMO 59-GAAGTGCCCTTGGTTCGGACA-39
59-CCGCCAGTCAGCCACGAAT-39
GLI1 59-CAGGGAGTGCAGCCAATACAG-39
59-GAGCGGCGGCTGACAGTATA-39
59-TCTCAAAGTG-
GGAGGCACAA-39
59-CCCTTAGGAA-
ATGCGATCTG-39
GLI2 59-AGAAGCAGCGCAATGACGTG-39
59-GTCATCCAGTGCCGTCAGGT-39
doi:10.1371/journal.pone.0017687.t002
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maximum of 35%.
(DOC)
Table S2 Limiting dilution assay for spheroid colony
formation. Mice were only treated cyclopamine at the right rear
flank or control tomatidine at the left rear flank (twice a week for 3
weeks) when tumors from HGC-27 tumorsphere cells reached
about 2 mm, after 3 weeks, we performed a limiting dilution assay
for spheroids formation using tumor cells treated with cyclopamine
and treated with tomatidine, respectively. Approximately 9–15% of
cells from xenotransplanted tumor treated with tomatidine could
produce spheroids, while less than 2.5% of cells from xenotrans-
planted tumor treated with cyclopamine could generate spheroids.
Therefore, blocking SHH pathway in vivo could reduce the
numbers of gastric CSLCs. Tom=tomatidine, Cyc=cyclopamine.
(DOC)
Table S3 Case description and tumor features. The
human fresh, sterile gastric cancer tissue specimens were obtained
in accordance with the ethical standards of the institutional
committee on human experimentation from 15 patients (age range
70–85 years) undergoing a gastric cancer resection, after obtaining
informed consent from the patients.
(DOC)
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